PRESENTATIONS
|
|
|
|
|
|
08:00 – 08:15CCVM Welcome C. Hengstenberg, G. Laufer |
|
|
|
08:15 – 08:45Keynote Lecture: Cardiovascular Medicine – A plea for curative medicine A. Haverich |
|
|
|
|
|
|
|
09:00 – 09:10Case presentations C. Nitsche, P. Werner |
|
|
|
09:10 – 12:00Live case I: Aortic Valve – TAVI (Interventional) C. Hengstenberg, G. Goliasch |
|
|
|
09:10 – 12:00Live case II: Aortic Valve – TAVI (RAM or Homograft) M. Andreas, A. Haverich |
|
|
|
09:20 – 09:30Developments in cerebral embolic protection G. Weisz |
|
|
|
09:30 – 09:40Developmens in SAVR: The Ozaki procedure M. Krane |
|
|
|
10:30 – 10:35Sapien3 / ultra W.-K. Kim |
|
|
|
10:35 – 10:40Evolute R / pro R. K. Binder |
|
|
|
10:40 – 10:45Acurate neo O. Husser |
|
|
|
10:45 – 10:50Portico A. Geppert |
|
|
|
10:50 – 10:55Our experience with Myval THV D. Jagielak |
|
|
|
10:55 – 11:05The right valve for the right patient – between economics and data A. Cribier |
|
|
|
11:05 – 11:45Live case III: Aortic Valve – TAVI (interventional) C. Hengstenberg |
|
|
|
11:45 – 12:00TAVI in low risk patients – ready for prime time? S. Windecker |
|
|
|
12:00 – 12:15SAVR in 2020 – still the gold standard? G. Laufer |
|
|
|
12:15 – 12:30The HeartTeam on Stage: Low risk TAVI – blessing or curse A. Haverich, A. Cribier, G. Weisz, G. Dangas, T. Schmitz |
|
|
|
|
|
|
|
12:45 – 13:05TripClip – Experience A. Zirlik |
|
|
|
13:05 – 13:25MitraClip – Experience M. Andreas |
|
|
|
13:25 – 13:45Tendyne – Update & Outlook A. Zierer |
|
|
|
|
|
|
|
14:15 – 14:25Case presentations P. Bartko, M. Mach |
|
|
|
14:25 – 15:00Live case IV: Tricuspid Valve (Interventional) J. Mascherbauer, J. Hausleiter |
|
|
|
14:25 – 15:00Live case V: Tricuspid Valve (Surgical) L. Müller, A. Kocher |
|
|
|
15:00 – 15:15Functional tricuspid regurgitation – when to intervene? G. Dreyfus |
|
|
|
15:15 – 15:30The role of imaging in tricuspid interventions F. Kreidel |
|
|
|
15:30 – 15:45Technique and outcomes of surgical tricuspid valve repair F. van Praet |
|
|
|
15:45 – 16:00Surgical tricuspid valve replacement R. Seitelberger |
|
|
|
16:00 – 16:15Transcatheter tricuspid valve repair – emerging evidence F. Kreidel |
|
|
|
16:15 – 16:30Transcatheter tricuspid valve replacement – a feasable concept? H. Figulla |
|
|
|
16:30 – 16:45The HeartTeam on Stage: Tricuspid repair – the ideal patient A. Calafiore, G. Dreyfus, H. Figulla, F. Kreidel |
|
|
|
|
|
|
|
17:15 – 17:30Quantification of Functional Mitral Regurgitation G. Goliasch |
|
|
|
17:30 – 17:45Transcatheter MV Interventions in FMR – Lessons learned in 2019 J. Hausleiter |
|
|
|
17:45 – 18:00Surgical MV Repair in FMR – New Horizons A. Calafiore |
|
|
|
18:00 – 18:15Novel Solutions for the Mitral Valve M. Andreas |
|
|
|
|
|
|
|
08:15 – 08:45Personalized Medicine in Cardiovascular Disease G. Dangas |
|
|
|
|
|
|
|
09:00 – 09:20Case presentations M. Mach, P. Werner |
|
|
|
09:00 – 09:20Live case VI: Structural Intervention (TAVI + LAA-Verschluss) M. Andreas, K. Neven |
|
|
|
09:00 – 09:20Live case VII: Mitral Repair with combined MAZE N. Ad, S. Mahr |
|
|
|
10:30 – 10:40PFO – to close B. Meier |
|
|
|
10:40 – 10:50PFO – or not to close S. Greisenegger |
|
|
|
10:50 – 11:05Surgical LAA exclusion S. Benussi |
|
|
|
11:05 – 11:20Interventional LAA closure U. Landmesser |
|
|
|
11:20 – 11:35Fire or Ice – Afib ablation in 2020 K.-H. Kuck |
|
|
|
11:35 – 11:50Surgical ablation in 2020 N. Ad |
|
|
|
|
|
|
|
12:15 – 12:35Live in the Box: Cinching the Mitral Apparatus to Treat FMR M. Yildiz |
|
|
|
12:35 – 12:55First experiences with Allegra at AKH Vienna P. Simon |
|
|
|
12:55 – 13:15Successful revascularization – The patient's perspective C. Jensen |
|
14:00 – 15:40 HEART-TEAM – RECAP & OUTLOOK
CORONARY REVASCULARIZATION (click to enlarge)
|
|
|
|
|
|
|
14:00 – 14:15Update on non-invasive coronary imaging C. Gebhard |
|
|
|
14:15 – 14:30Arterial grafting in CABG in 2020 M. Gaudino |
|
|
|
14:30 – 14:45ISCHEMIA trial – what to do in stable disease? G. Hage |
|
|
|
14:45 – 15:00CTO trial update – what to do with the occluded vessel ? J. Spratt |
|
|
|
15:00 – 15:15What we can learn from the TiCAB trial? S. Sandner |
|
|
|
15:15 – 15:30Excel Trial revisited – consequences and lessons learned T. Doenst |
|